| 描述 | 这株细胞1995年10月13日最初来源于原发性导管癌, 用了11.5个月建株。肿瘤分类为TNM IIB期, 3级。BRCA1分析表明这株细胞是BRCA1 5382C突变纯合的, 而来源于同一病人的类淋巴母细胞细胞株在这个突变位点上是杂合的。 另两个家庭成员也有这个突变; 一个同卵双生姐妹也患有乳腺癌。这株细胞有一个后天的TP53突变, 而其野生型等位基因丢失; 一个PTEN基因的后天的纯合缺失, 以及多个与乳腺癌发病机理相关的位点上发生的杂合突变。这株细胞Her2-neu和p53表达都呈阴性。 HCC1937的上皮细胞特异性标志上皮细胞糖蛋2(EGP2)和细胞角蛋白19都呈阳性。雌激素受体(ER)和孕酮(PR)表达阴性。来源于同一患者的EBV转化的类淋巴母细胞株(HCC1937BL)也有供应, ATCC目录号为CRL-2337。 |
| REFERENCE | Tomlinson GE et al. Chaacterization of a breast cancer cell line derived from a germ-line BRCA1 mutation. Cancer Res. 58:3237-3242, 1998 PubMed: 98363228Gazdar AF et al. Charaterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998 PubMed: 99049517Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.Centers for Disease Control (1993), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 3rd Edition U.S. Government Printing Office Washington D.C. |
